CollaGenex touts Phase IV Oracea data

CollaGenex Pharmaceuticals says that a post-approval study of Oracea in combination with Galderma Laboratories' MetroGel skin treatment demonstrated a significant advantage over the MetroGel therapy combined with a placebo in clearing up rosacea. Volunteers taking the combined Oracea-MetroGel therapy experienced an average 66.4 percent reduction in skin inflammation compared to a 48.2 percent average for MetroGel combined with a placebo. After dropping MetroGel from the combinations, the Oracea group continued to maintain their improvement while the placebo group worsened. Oracea was approved by the FDA last May.

- see the release on the results
- here's the AP report on the trial data

Related Article:
FDA OKs Oracea for rosacea skin condition. Report